Wuhan Hiteck Biological Pharma Co Ltd

Wuhan Hiteck Biological Pharma Co Ltd exhibits a strong liquidity position, with a current ratio of 3.98, indicating that it holds nearly four times more current assets than current liabilities. However, the company reported negative operating cash flow of -76.5 million CNY and free cash flow of -206.5 million CNY, suggesting ongoing cash burn despite its strong balance sheet. The company's debt-to-equity ratio is 0.04, reflecting a conservative capital structure with minimal leverage. Profitability metrics are negative, with a return on equity of -10.7% and a return on assets of -8.98%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of 231.3 million CNY and an operating loss of 234.3 million CNY, indicating a challenging operating environment. Gross profit of 217.2 million CNY on revenue of 541.4 million CNY suggests a gross margin of approximately 40%, which is in line with industry norms but insufficient to offset operating expenses. The company's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic diversification in the latest financials. The lack of segmental or geographic breakdown in the input data limits the ability to assess exposure to specific markets or product lines. The company's growth trajectory is currently negative, with a net loss and declining cash flow. No forward-looking revenue guidance is provided in the input data, and the absence of a clear growth strategy or product pipeline in the narrative suggests limited visibility into future performance. The company's capital expenditures of -50.5 million CNY indicate ongoing investment in infrastructure or R&D, but the negative sign suggests these are cash outflows. The risk assessment highlights medium liquidity risk due to negative operating and free cash flows, despite a strong current ratio. The company's dilution risk is rated as low, with no significant dilution events or share issuance plans disclosed in the input data. The risk of dilution is further mitigated by the fact that basic and diluted shares outstanding are equal, indicating no material dilutive impact from stock options or convertible securities. Recent events or filings are not explicitly detailed in the input data, but the company's financial performance suggests a period of operational stress. The absence of positive earnings or cash flow generation may prompt investors to monitor future filings for signs of strategic shifts or cost-cutting measures.